ResearcherDalian Medical UniversityNo recent work listed

Xu Zheng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5705-0381; OpenAlex author ID A5101503153. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 10

Papers, trials and grants by year

2022: 2 papers

Papers 2

Design, synthesis and activity evaluation of isopropylsulfonyl-substituted 2,4- diarylaminopyrimidine derivatives as FAK inhibitors for the potential treatment… Co-author DOI 10.1016/j.ejmech.2022.114607 ↗
Rosmarinic Acid Decreases the Malignancy of Pancreatic Cancer Through Inhibiting Gli1 Signaling. Co-author DOI 10.1016/j.phymed.2021.153861 ↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Xing Li · 1 shared paper, 2022 · strength 0.15
- Paper Design, synthesis and activity evaluation of isopropylsulfonyl-substituted 2,4- diarylaminopyrimidine derivatives as FA… DOI 10.1016/j.ejmech.2022.114607 ↗
Xiaodong Ma · 1 shared paper, 2022 · strength 0.15
- Paper Design, synthesis and activity evaluation of isopropylsulfonyl-substituted 2,4- diarylaminopyrimidine derivatives as FA… DOI 10.1016/j.ejmech.2022.114607 ↗
Changyuan Wang · 1 shared paper, 2022 · strength 0.15
- Paper Design, synthesis and activity evaluation of isopropylsulfonyl-substituted 2,4- diarylaminopyrimidine derivatives as FA… DOI 10.1016/j.ejmech.2022.114607 ↗
Yanxia Li · 1 shared paper, 2022 · strength 0.15
- Paper Design, synthesis and activity evaluation of isopropylsulfonyl-substituted 2,4- diarylaminopyrimidine derivatives as FA… DOI 10.1016/j.ejmech.2022.114607 ↗
Chunmei Wen · 1 shared paper, 2022 · strength 0.15
- Paper Rosmarinic Acid Decreases the Malignancy of Pancreatic Cancer Through Inhibiting Gli1 Signaling. DOI 10.1016/j.phymed.2021.153861 ↗
Xiang Zhou · 1 shared paper, 2022 · strength 0.15
- Paper Rosmarinic Acid Decreases the Malignancy of Pancreatic Cancer Through Inhibiting Gli1 Signaling. DOI 10.1016/j.phymed.2021.153861 ↗
Wei‐Ming Wang · 1 shared paper, 2022 · strength 0.15
- Paper Rosmarinic Acid Decreases the Malignancy of Pancreatic Cancer Through Inhibiting Gli1 Signaling. DOI 10.1016/j.phymed.2021.153861 ↗
Jie Deng · 1 shared paper, 2022 · strength 0.15
- Paper Rosmarinic Acid Decreases the Malignancy of Pancreatic Cancer Through Inhibiting Gli1 Signaling. DOI 10.1016/j.phymed.2021.153861 ↗
Qingqing Ruan · 1 shared paper, 2022 · strength 0.15
- Paper Rosmarinic Acid Decreases the Malignancy of Pancreatic Cancer Through Inhibiting Gli1 Signaling. DOI 10.1016/j.phymed.2021.153861 ↗
Yongheng Bai · 1 shared paper, 2022 · strength 0.15
- Paper Rosmarinic Acid Decreases the Malignancy of Pancreatic Cancer Through Inhibiting Gli1 Signaling. DOI 10.1016/j.phymed.2021.153861 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.